Documents
Application Sponsors
Marketing Status
Prescription | 001 |
Prescription | 002 |
Prescription | 003 |
Application Products
001 | TABLET;ORAL | 10MG | 2 | QULIPTA | ATOGEPANT |
002 | TABLET;ORAL | 30MG | 2 | QULIPTA | ATOGEPANT |
003 | TABLET;ORAL | 60MG | 2 | QULIPTA | ATOGEPANT |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2021-09-28 | PRIORITY |
Submissions Property Types
TE Codes
001 | Prescription | TBD |
002 | Prescription | TBD |
003 | Prescription | TBD |
CDER Filings
ABBVIE INC
cder:Array
(
[0] => Array
(
[ApplNo] => 215206
[companyName] => ABBVIE INC
[docInserts] => ["",""]
[products] => [{"drugName":"QULIPTA","activeIngredients":"ATOGEPANT","strength":"10MG","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"","rld":"TBD","rs":"No"},{"drugName":"QULIPTA","activeIngredients":"ATOGEPANT","strength":"30MG","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"","rld":"TBD","rs":"No"},{"drugName":"QULIPTA","activeIngredients":"ATOGEPANT","strength":"60MG","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"","rld":"TBD","rs":"No"}]
[labels] => [{"actionDate":"09\/28\/2021","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/215206Orig1s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"09\/28\/2021","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 1 - New Molecular Entity","reviewPriority":"PRIORITY","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/215206Orig1s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2021\\\/215206Orig1s000ltr.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2021-09-28
)
)